Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

BTK Inhibitor

Pirtobrutinib, LOXO-305

BTK Inhibitor

Wu J, et al1; Singh SP, et al2

Bruton tyrosine kinase (BTK) inhibitors represent a major therapeutic advance in the treatment of patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies by inducing durable responses.3-5  BTK is critical for propagation of B-cell receptor signaling and is upregulated in CLL cells as compared with normal B cells. BTK inhibition, both in vitro and vivo, decreases proliferation and survival signals.3
Pirtobrutinib (LOXO-305) is a next-generation, highly selective, oral, noncovalent BTK inhibitor. It possesses nanomolar potency independent of BTK C481 status in enzyme and cell-based assays. Pirtobrutinib has been shown in vitro to be 300-fold more selective for BTK, for over 98% of the 370 kinases tested, with no significant inhibition of nonkinase off targets at 1 µM.6
Clinical Development
Pirtobrutinib is being investigated in clinical trials in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, or non-Hodgkin’s lymphoma.


  1. Wu J, et al. J Hematol Oncol. 2016;9(1):80.
  2. Singh SP, et al. Mol Cancer. 2018;17(1):57.
  3. Woyach JA, et al. J Clin Oncol. 2017;35(13):1437-1443.
  4. Mato AR, et al. Blood. 2016;128(18):2199-2205.
  5. Byrd JC, et al. N Eng J Med. 2016;374(4):323-332.
  6. Gomez EB, et al. Blood. 2019;134(suppl 1):4644.

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.


IDH1 Inhibitor

Learn More

PDGFRα Antibody

Learn More

VEGF Receptor-2 Antagonist

Learn More